Skip to main content
. 2016 Jul 9;7(50):82213–82227. doi: 10.18632/oncotarget.10511

Figure 6. Different clinical implication of SMAD4 expression in EBV-positive and EBV-negative stomach cancer patients.

Figure 6

(A) Representative microscopic images of the histologic features of EBV-positive stomach cancer tissues. In-situ hybridization for EBV-encoded small RNAs (EBER) showed black signals in almost all of the cancer cell nuclei. NFκB and SMAD4 immunohistochemistry was evaluated only nuclear staining of cancer cells. (B) Kaplan-Meier survival curves. The ‘SMAD4 loss’ group (solid line) tended to show a worse survival rate than the ‘SMAD4 preserved’ group (dotted line) among EBV-positive cancer patients (P = 0.08), whereas SMAD4 had no prognostic significance in EBV-negative patients.